Pan, Ling http://orcid.org/0000-0003-2403-1672
Feigin, Andrew
Article History
Accepted: 13 January 2021
First Online: 14 February 2021
Compliance with Ethical Standards
:
: Ling Pan declares that she has no conflict of interest. Andrew Feigin has consulted for NeuExcell Therapeutics, Voyager Therapeutics and Stealth BioTherapeutics. He has received grant support from Vaccinex, and Prilenia Therapeutics.
: This article does not contain any studies with human participants or animals performed by any of the authors.